Skip Navigation


Rheumatology Advance Access originally published online on July 20, 2004
Rheumatology 2004 43(10):1300-1304; doi:10.1093/rheumatology/keh323
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
43/10/1300    most recent
keh323v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Butrimiene, I.
Right arrow Articles by Zvirbliene, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Butrimiene, I.
Right arrow Articles by Zvirbliene, A.
Related Collections
Right arrow Spondylarthropathies
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 10 © British Society for Rheumatology 2004; all rights reserved

Paper

Different cytokine profiles in patients with chronic and acute reactive arthritis

I. Butrimiene, S. Jarmalaite1, J. Ranceva, A. Venalis, L. Jasiuleviciute and A. Zvirbliene2

Institute of Experimental and Clinical Medicine, Vilnius University, 1 Laboratory of Ecological Genetics, Vilnius University and 2 Laboratory of Immunology, Institute of Biotechnology, Lithuania.

Correspondence to: I. Butrimiene, Department of Rheumatology, Vilnius University Institute of Experimental and Clinical Medicine, Zygimantu 9, LT-2600, Vilnius, Lithuania. E-mail: irena.butrimiene{at}santa.lt

Objective. Analysis of cytokine production in patients with acute and chronic reactive arthritis (AcReA/ChrReA) in order to search for new treatment possibilities.

Methods. Cytokine production by peripheral blood and synovial fluid mononuclear cells (PBMCs/SFMCs) of 28 patients with AcReA, 27 patients with ChrReA, 26 patients with rheumatoid arthritis (RA) and 31 healthy controls was analysed by enzyme-linked immunosorbent assay (ELISA) and flow-cytometry. Production of tumour necrosis factor-alpha (TNF-{alpha}), interferon-gamma (IFN-{gamma}) and interleukin (IL)-10 was measured by ELISA, while the percentages of TNF-{alpha}-, IFN-{gamma}- and IL-4-positive CD3+ cells were determined in the same groups of patients and healthy subjects using flow cytometry.

Results. Spontaneous TNF-{alpha} production observed in PBMCs of ChrReA, but not of AcReA, patients was significantly higher (P<0.001) than in healthy controls. The percentages of TNF-{alpha}-positive CD3+ blood cells in ChrReA exceeded that of RA patients and healthy controls (P<0.05 and P<0.001, respectively). Also, the percentages of IFN-{gamma}-positive CD3+ cells were significantly higher in peripheral blood and synovial fluid of ChrReA patients (P<0.05 and P<0.05, respectively) as compared with AcReA. In ChrReA spontaneous IL-10 production in PBMCs was similar to that observed in healthy controls, while in RA and AcReA the production of IL-10 was significantly increased (P<0.05 and P<0.05, respectively). IL-4 production was low in all study groups with no significant differences detected.

Conclusions. High production of TNF-{alpha} and IFN-{gamma} detected in ChrReA supports the possible use of anti-TNF-{alpha} treatment in ChrReA.

KEY WORDS: Reactive arthritis, Cytokines, TNF-{alpha}, IFN-{gamma}


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.